We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
Madrigal Pharmaceuticals
An SI Board Since April 2018
Posts SubjectMarks Bans Symbol
110 15 0 MDGL
Emcee:  Lynn Type:  Moderated
"Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The company‚Äôs lead candidate, MGL-3196, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist in clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and familial dyslipidemias/hypercholesterolemias, among other related indications. [source:]"

MDGL has been up well over 600% the past year!

Besides discussion and new on MDGL, discussion of other pharmaceudicals working on NASH is welcome. Some of these are VKTX, GLMD, ICPT , GNFTF , GILD, and PFE (for which there is a thread here at SI).
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
110<Few details were unveiled about that deal, which concerned two undisclosed tMiljenko Zuanic-July 2
109B-I licenses dual-acting NASH candidate: investorshub.advfn.comDewDiligence_on_SI-July 1
108A competitor with a singular focus on NASH via activation of most - but not all tuck-June 20
107I poked around in the CRO's website. They have two sites in San Antonio andtuck1May 21
106Because of the Pinnacle Clinical Research involvement, we may not know which (hoMiljenko Zuanic-May 21
105Worried? What for? Just enjoy another $60-70/share decline...(just kiding). I reMiljenko Zuanic-May 15
104"An experienced group of NASH investigators and clinical sites around the wtuck-May 14
103I am in Croatia, slow respond. Longer trial is must, surrogate/biopsy (samplingMiljenko Zuanic-May 3
102I don't think I learned anything of consequence from reading those tweets.DewDiligence_on_SI-April 30
101Interesting "tweetorial" from a nephrologist, concerning NASH trial outuck-April 30
100<These big companies seem to have more disasters than successes on buyouts.&gMiljenko Zuanic-April 16
99You have the MDGL/VKTX drugs. The various GILD/GNFT/NGM drugs. Now these GLP-1 dJamesK-April 16
98Can not figure it out how was I fooled by the false and excessive hype of the imMiljenko Zuanic1April 15
97< I have significantly reduced my mdgl position simply due to all the bad macMiljenko Zuanic-April 12
96Thanks for sharing your thoughts. A year ago I thought NASH market (if it achiekeokalani'nui-April 12
95Will 3196 prove sufficiently strong to compete with single MoA? Possible but unlDewDiligence_on_SI-April 12
94You guys all but predicted a combination including GLP-1. Nice work.DewDiligence_on_SI-April 12
93GILD/NOVO going with triple (with GLP-1), while MDGL is firing away. Miljenko Zuanic-April 12
92Thanks. It is not secret that wast majority of the NASH pts are obese/pre-diabeMiljenko Zuanic-April 5
91Deletedtuck-April 4
90This review from 2018 suggests you are correct. >>No phkeokalani'nui-April 4
89I don't know the reason for GLP-1 and vitamin-E exclusions. Are there any DDDewDiligence_on_SI-April 4
88What about second part, GLP-1 agonist? Is that most prospective NASH compound, aMiljenko Zuanic-April 4
87HbA1c >=9% suggests a compliance problem, so it's probably a good idea toDewDiligence_on_SI-April 4
86Why they are excluding diabetic population: <Exclusion Criteria: History of sMiljenko Zuanic-April 4
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):